6 research outputs found
Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome
In addition to lowering blood pressure, telmisartan, an angiotensin (AT(1)) receptor blocker, has recently been shown to exert pleiotropic effects as a partial agonist of nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma). On the basis of these findings and docking pose similarity between telmisartan and rosiglitazone in PPAR gamma active site, two classes of benzimidazole derivatives were designed and synthesized as dual PPAR gamma agonist/angiotensin II antagonists for the possible treatment of metabolic syndrome. Compound 4, a bisbenzimidazole derivative showed the best affinity for the AT(1) receptor with a K(i) = 13.4 nM, but it was devoid of PPAR gamma activity. On the other hand 9, a monobenzimidazole derivative, showed the highest activity in PPAR gamma transactivation assay (69% activation) with no affinity for the AT(1) receptor. Docking studies lead to the designing of a molecule with dual activity, 10, with moderate PPARgamma activity (29%) and affinity for the AT(1) receptor (K(i) = 2.5 microM)
Design, synthesis, and docking studies of novel telmisartan–glitazone hybrid analogs for the treatment of metabolic syndrome
Design, synthesis, and docking studies of telmisartan analogs for the treatment of metabolic syndrome
Discovery of Clinical Candidate 1‑{[(2<i>S</i>,3<i>S</i>,4<i>S</i>)‑3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin‑1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design
Through
fragment-based drug design focused on engaging the active
site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient
manner, a micromolar hit identified from a screen of a Pfizer fragment
library was optimized to afford IRAK4 inhibitors with nanomolar potency
in cellular assays. The medicinal chemistry effort featured the judicious
placement of lipophilicity, informed by co-crystal structures with
IRAK4 and optimization of ADME properties to deliver clinical candidate
PF-06650833 (compound <b>40</b>). This compound displays a 5-unit
increase in lipophilic efficiency from the fragment hit, excellent
kinase selectivity, and pharmacokinetic properties suitable for oral
administration